myo-inositol/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases preterm birth incidence
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“However, myo-inositol may be associated with a reduction in the incidence of preterm birth (RR 0.35, 95% CI 0.17 to 0.70; 4 studies; 829 infants).”
Quoted verbatim from Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes.. - Study
- meta-analysis
- Participants
- 829
- Population
- Pregnant women 10 to 24 weeks pregnant at the start of the trials, pooled across four randomised trials (829 infants)
Effect 0.35 risk ratio, 95% CI 0.17 to 0.7
Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes.2023PMID:36790138Permalink
Keep reading
- Everything the graph holds on myo-inositol
- Every compound studied against Preterm birth incidence
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M45QS51986B3STZXSF4YZVKX